Home › Research › Treatments
Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trial
Koch G, Assogna M, Gadola Y, Alberici A, Di Lorenzo F, Bonnì S, Borghi I, Cerulli Irelli E et al.. The Lancet regional health. Europe, 2025-08-05
Topic: Risk, prevention and care in population studies
Plain-language summary
Clinical and experimental evidence suggest that dopaminergic transmission is impaired in FTD. No significant effect was found on secondary outcome measures.
What this study adds
Evidence grade: High
The record lists 128 participants. The drug rotigotine did not show a significant effect on the secondary outcome measures in people with frontotemporal dementia. This means it did not demonstrate benefit for those measures in this trial.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Koch, G., Assogna, M., Gadola, Y., Alberici, A., Di Lorenzo, F., Bonnì, S., et al. (2025). Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trial. The Lancet regional health. Europe. https://doi.org/10.1016/j.lanepe.2025.101409
Vancouver
Koch G, Assogna M, Gadola Y, Alberici A, Di Lorenzo F, Bonnì S, et al. Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trial. The Lancet regional health. Europe. 2025. doi:10.1016/j.lanepe.2025.101409. PMID: 40809903.
BibTeX
@article{koch2025-40809903,
author = {Koch, G. and Assogna, M. and Gadola, Y. and Alberici, A. and Di Lorenzo, F. and Bonnì, S. and Borghi, I. and Cerulli Irelli, E. and others},
title = {{Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trial}},
journal = {The Lancet regional health. Europe},
year = {2025},
doi = {10.1016/j.lanepe.2025.101409},
pmid = {40809903},
url = {https://doi.org/10.1016/j.lanepe.2025.101409}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Clinical and experimental evidence suggest that dopaminergic transmission is impaired in FTD.
- No significant effect was found on secondary outcome measures.
Why it matters
The drug rotigotine did not show a significant effect on the secondary outcome measures in people with frontotemporal dementia. This means it did not demonstrate benefit for those measures in this trial.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants128
- Evidence strengthHigh
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Lancet regional health. Europe) |
| Journal's citation record | 1 / 4 | The Lancet Regional Health - Europe: journal h-index 88 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 128 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Barbara Borroni: h-index 88 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Sapienza University of Rome: institution h-index 1,145 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40809903) |
| Free to read | 2 / 2 | Free to read |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.lanepe.2025.101409
- PubMed: 40809903
- Original source →
- Free full text: The Lancet Regional Health - Europe →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.